• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    1/9/24 8:06:02 AM ET
    $APLM
    $AURA
    $CYCC
    $EFTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APLM alert in real time by email

    Gainers

    • Aura Biosciences (NASDAQ:AURA) stock moved upwards by 44.3% to $13.0 during Tuesday's pre-market session. The company's market cap stands at $640.3 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares rose 40.01% to $0.21. The company's market cap stands at $11.3 million.
    • Jin Medical International (NASDAQ:ZJYL) stock moved upwards by 31.99% to $120.0. The company's market cap stands at $930.0 million.
    • Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 26.91% to $1.98. The company's market cap stands at $255.9 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 22.83% to $0.24. The company's market cap stands at $4.2 million.
    • Elicio Therapeutics (NASDAQ:ELTX) shares increased by 22.37% to $9.57. The market value of their outstanding shares is at $91.9 million.

    Losers

    • Grifols (NASDAQ:GRFS) shares declined by 35.2% to $7.21 during Tuesday's pre-market session. The company's market cap stands at $4.8 billion.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock fell 19.26% to $0.45. The company's market cap stands at $28.8 million.
    • Trevena (NASDAQ:TRVN) stock decreased by 10.25% to $0.66. The market value of their outstanding shares is at $10.0 million.
    • Apollomics (NASDAQ:APLM) shares fell 10.05% to $0.84. The market value of their outstanding shares is at $74.8 million.
    • Societal CDMO (NASDAQ:SCTL) stock decreased by 9.19% to $0.34. The market value of their outstanding shares is at $36.1 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares decreased by 8.47% to $2.92. The company's market cap stands at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM
    $AURA
    $CYCC
    $EFTR

    CompanyDatePrice TargetRatingAnalyst
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Aura Biosciences Inc.
    $AURA
    11/26/2025$13.00Outperform
    Evercore ISI
    Aura Biosciences Inc.
    $AURA
    5/28/2025$22.00Buy
    H.C. Wainwright
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    Seres Therapeutics Inc.
    $MCRB
    10/24/2024Neutral → Underweight
    JP Morgan
    Aura Biosciences Inc.
    $AURA
    7/25/2024$21.00Buy
    H.C. Wainwright
    Grifols S.A.
    $GRFS
    3/12/2024Hold → Sell
    Deutsche Bank
    More analyst ratings

    $APLM
    $AURA
    $CYCC
    $EFTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Michael bought $98,000 worth of shares (20,000 units at $4.90), increasing direct ownership by 14% to 166,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:43:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S bought $245,000 worth of shares (50,000 units at $4.90) and sold $7,823 worth of shares (1,519 units at $5.15), increasing direct ownership by 574% to 56,933 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:34:24 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

    4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

    1/2/25 4:12:36 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Kender Richard N

    4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

    3/6/26 4:36:52 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Henn Matthew R

    4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

    3/6/26 4:35:04 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Thorell Marella

    4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

    3/6/26 4:33:50 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Elicio Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $17.00

    3/10/26 8:40:26 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI resumed coverage on Aura Biosciences with a new price target

    Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00

    11/26/25 8:36:10 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Aura Biosciences with a new price target

    H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00

    5/28/25 9:07:05 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    SEC Filings

    View All

    SEC Form F-3 filed by Apollomics Inc.

    F-3 - Apollomics Inc. (0001944885) (Filer)

    3/9/26 5:16:51 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Elicio Therapeutics Inc.

    S-3/A - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/2/26 4:05:36 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Seres Therapeutics Inc.

    8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

    3/2/26 4:05:10 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

    Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program

    3/2/26 4:05:00 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

    BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: Company presentationDate: Wednesday, March 4, 2026Time: 1:10 PM ET The live webcast and replay of the presentation will be available HERE and on Elicio's Events page for 90 days follow

    2/25/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aura Biosciences to Participate in Upcoming Investor Conferences

    BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026. Fireside Chat at 9:10 a.m. ET. Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Fireside Chat at 3:40 p.m. ET. The Citizens Life Sciences Conference on Wednesday, March 11, 2026. Fireside Chat at 11:20 a.m. ET. The live webcasts of the fireside chats will be available

    2/25/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

    Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program

    3/2/26 4:05:00 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these

    11/5/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

    CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 8471287. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website shortly after the event and will be archi

    10/30/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $AURA
    $CYCC
    $EFTR
    Leadership Updates

    Live Leadership Updates

    View All

    Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

    Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early-stage live biotherapeutic programs in Inflammatory and immune diseases and supporting the read-out of clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkp

    2/12/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

    Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres' portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases highlighting new insights into the functional mechanism and clinical impact of VOWST™. Together, these publications provide further va

    1/6/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations